← Leaderboards
Kim N Danforth
Kaiser Foundation Research Institute
$2,088,303
Attributed
$2,279,678
Total exposure
3
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $714.9K · FY2014–20$1M$750K$500K$250K$0
'14
'15
'16
'17
'18
'19
'20
Funding mix
By agency
AHRQ$1,495,284 · 1
NIH$784,394 · 2
By mechanism
R01$1,495,284 · 1
R21$784,394 · 2
Top collaborators
- Aniket A Kawatkar2 shared
Most similar at Kaiser Foundation Research Institute
Same institution · by research overlap
- Marilyn L Kwan$12,106,221
- Carmit Kurn McMullen$5,401,038
- Lawrence H Kushi$60,993,337
- Matthew E. Nielsen$291,721
- Aniket A Kawatkar$3,696,730
Others in their field
Top investigators on “Malignant Neoplasms”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,074,554,219
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Richard K. Wilson · Washington University$274,272,747
- Larry Arthur$223,443,122
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
Research focus
Malignant NeoplasmsReportingEpidemiologistMalignant Neoplasm Of Urinary BladderPopulation HeterogeneityRecurrenceCharacteristicsElectronic Health RecordFutureImageNeoplasm RegistryPatient CareBladder NeoplasmPreventCaliforniaCaringCodeDiagnosisExcisionCancer PatientCancer RecurrenceGeneticBaseTumor
Grant awards (7)
Development of an automated method to capture bladder cancer recurrence and progression for epidemiologic research$210,481
R21 · FY2020 · CA
Development of an automated method to capture bladder cancer recurrence and progression for epidemiologic research$172,270
R21 · FY2019 · CA
Electronic Clinical Surveillance to Measure and Improve Safety in Ambulatory Care$499,874
R01 · FY2017 · HS · contact PI
Electronic Clinical Surveillance to Measure and Improve Safety in Ambulatory Care$497,842
R01 · FY2016 · HS · contact PI
Electronic Clinical Surveillance to Measure and Improve Safety in Ambulatory Care$497,568
R01 · FY2015 · HS · contact PI
Trends and Disparities in Bladder Cancer Treatment$217,348
R21 · FY2015 · CA · contact PI
Trends and Disparities in Bladder Cancer Treatment$184,295
R21 · FY2014 · CA · contact PI